Suppr超能文献

胃癌中CD39的高表达会降低根治性切除术后患者的预后。

High expression of CD39 in gastric cancer reduces patient outcome following radical resection.

作者信息

Cai Xiao-Yan, Wang Xue-Fei, Li Jun, Dong Jiang-Nan, Liu Jiang-Qi, Li Neng-Ping, Yun Bei, Xia Rong-Long, Qin Jing, Sun Yi-Hong

机构信息

Department of General Surgery, Gongli Hospital, Shanghai 200135, P.R. China.

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.

出版信息

Oncol Lett. 2016 Nov;12(5):4080-4086. doi: 10.3892/ol.2016.5189. Epub 2016 Sep 26.

Abstract

Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), also known as cluster of differentiation (CD)39, is the rate-limiting enzyme in the generation of immunosuppressive adenosine and is important in tumor progression. The present study evaluated the expression of CD39 and CD39 forkhead box P3 (FoxP3) regulatory T (Treg) cells in gastric cancer (GC), and determined their prognostic roles in patients with GC following radical resection. It was observed that CD39 was expressed at significantly higher rates in tumor tissues as compared with paired peritumoral tissues. Overexpression of tumor CD39 was correlated with overall survival (OS). Furthermore, CD39 expression in GC tissues exhibited a prognostic role in OS. The CD39 FoxP3/FoxP3 ratio in tumor tissues was higher than that in paired peritumoral tissues, and CD39 FoxP3 Treg cells were a better prognostic indicator than FoxP3 Treg cells for OS. Collectively, our study indicates that overexpression of CD39 in GC is a predictor of poor outcome for GC patients following radical resection. CD39 FoxP3 Treg cells are a potential target for cancer immunotherapy.

摘要

胞外核苷三磷酸二磷酸水解酶1(ENTPD1),也称为分化簇(CD)39,是免疫抑制性腺苷生成中的限速酶,在肿瘤进展中起重要作用。本研究评估了CD39和CD39叉头框P3(FoxP3)调节性T(Treg)细胞在胃癌(GC)中的表达,并确定了它们在根治性切除术后GC患者中的预后作用。结果发现,与配对的瘤旁组织相比,肿瘤组织中CD39的表达率显著更高。肿瘤CD39的过表达与总生存期(OS)相关。此外,GC组织中CD39的表达在OS中具有预后作用。肿瘤组织中CD39 FoxP3/FoxP3比值高于配对的瘤旁组织,对于OS而言,CD39 FoxP3 Treg细胞是比FoxP3 Treg细胞更好的预后指标。总体而言,我们的研究表明,GC中CD39的过表达是GC患者根治性切除术后预后不良的预测指标。CD39 FoxP3 Treg细胞是癌症免疫治疗的潜在靶点。

相似文献

1
High expression of CD39 in gastric cancer reduces patient outcome following radical resection.
Oncol Lett. 2016 Nov;12(5):4080-4086. doi: 10.3892/ol.2016.5189. Epub 2016 Sep 26.
5
Circulating gluten-specific FOXP3CD39 regulatory T cells have impaired suppressive function in patients with celiac disease.
J Allergy Clin Immunol. 2017 Dec;140(6):1592-1603.e8. doi: 10.1016/j.jaci.2017.02.015. Epub 2017 Mar 8.
9
CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
J Immunol. 2009 Dec 1;183(11):7602-10. doi: 10.4049/jimmunol.0901881. Epub 2009 Nov 16.
10
Regulatory T cells in transplantation: does extracellular adenosine triphosphate metabolism through CD39 play a crucial role?
Transplant Rev (Orlando). 2010 Apr;24(2):52-66. doi: 10.1016/j.trre.2010.01.002. Epub 2010 Feb 11.

引用本文的文献

1
Liposomes, immune cells, and lung cancer subtypes: A bidirectional Mendelian randomization study.
Medicine (Baltimore). 2025 Jun 13;104(24):e42795. doi: 10.1097/MD.0000000000042795.
4
The role of metabolic reprogramming in kidney cancer.
Front Oncol. 2024 May 31;14:1402351. doi: 10.3389/fonc.2024.1402351. eCollection 2024.
5
Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms.
Recent Pat Anticancer Drug Discov. 2025;20(1):1-25. doi: 10.2174/0115748928269276231120103256.
6
Heterogeneity of the tumor immune microenvironment and clinical interventions.
Front Med. 2023 Aug;17(4):617-648. doi: 10.1007/s11684-023-1015-9. Epub 2023 Sep 20.
7
Nucleotide metabolism: a pan-cancer metabolic dependency.
Nat Rev Cancer. 2023 May;23(5):275-294. doi: 10.1038/s41568-023-00557-7. Epub 2023 Mar 27.
9
Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review.
Ther Adv Med Oncol. 2022 Nov 29;14:17588359221139625. doi: 10.1177/17588359221139625. eCollection 2022.
10
Adenosine signaling: Optimal target for gastric cancer immunotherapy.
Front Immunol. 2022 Sep 16;13:1027838. doi: 10.3389/fimmu.2022.1027838. eCollection 2022.

本文引用的文献

2
The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation.
J Autoimmun. 2015 Apr;58:12-20. doi: 10.1016/j.jaut.2014.12.007. Epub 2015 Jan 29.
3
High circulating CD39(+) regulatory T cells predict poor survival for sepsis patients.
Int J Infect Dis. 2015 Jan;30:57-63. doi: 10.1016/j.ijid.2014.11.006. Epub 2014 Nov 13.
4
Target tissue ectoenzyme CD39/CD73-expressing Foxp3+ regulatory T cells in patients with psoriasis.
Clin Exp Dermatol. 2015 Mar;40(2):182-91. doi: 10.1111/ced.12497. Epub 2014 Oct 4.
6
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
Curr Opin Immunol. 2014 Apr;27:16-25. doi: 10.1016/j.coi.2014.01.004. Epub 2014 Feb 14.
8
CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.
Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):367-72. doi: 10.1016/j.clml.2011.06.005.
9
Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer.
Purinergic Signal. 2011 Jun;7(2):231-41. doi: 10.1007/s11302-011-9228-9. Epub 2011 Apr 2.
10
Global cancer statistics.
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验